Cover Image
市場調查報告書

4SC AG的產品平台分析

4SC AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224615
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
4SC AG的產品平台分析 4SC AG - Product Pipeline Review - 2016
出版日期: 2016年07月20日 內容資訊: 英文 51 Pages
簡介

4SC AG是開發針對自體免疫疾病及癌症用標靶治療藥的製藥企業。

本報告提供4SC AG的治療藥開發平台現況及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

4SC AG的基本資料

  • 4SC AG概要
  • 主要資訊
  • 企業資料

4SC AG:R&D概要

  • 主要的治療範圍

4SC AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

4SC AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

4SC AG:藥物簡介

  • resminostat
  • vidofludimus
  • 4SC-202
  • 4SC-205
  • 4SC-X09
  • CR-2408
  • Small Molecule for Malaria
  • Small Molecule to Block Kv1.3 for Autoimmune Disorders
  • Small Molecule to Inhibit Cytokine for Psoriasis
  • Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders
  • Small Molecules to Agonize TLR 7 for Cancer
  • Small Molecules to Agonize TLR 8 for Cancer
  • SC-92366
  • Small Molecule to Inhibit GLI-1 for Cancer
  • Small Molecules for Cancer
  • Small Molecules for Neurological Disorders
  • Small Molecules to Antagonize H4 for Autoimmune and Inflammatory Diseases
  • Small Molecules to Inhibit Bromodomain for Cancer
  • Small Molecules to Inhibit Casein Kinase 1 for Cancer
  • Small Molecules to Inhibit MSK1 for Autoimmune Diseases and Cancer
  • Small Molecules to Inhibit MSK2 for Autoimmune Diseases and Cancer
  • Small Molecules to Inhibit PAD4 for Oncology

4SC AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

4SC AG:最近的開發平台趨勢

4SC AG:暫停中的計劃

4SC AG:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • 4SC-203
    • 4SC-207

4SC AG:企業發表

4SC AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08096CDB

Summary

Global Markets Direct's, '4SC AG - Product Pipeline Review - 2016', provides an overview of the 4SC AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by 4SC AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of 4SC AG
  • The report provides overview of 4SC AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses 4SC AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features 4SC AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate 4SC AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for 4SC AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 4SC AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • 4SC AG Snapshot
    • 4SC AG Overview
    • Key Information
    • Key Facts
  • 4SC AG - Research and Development Overview
    • Key Therapeutic Areas
  • 4SC AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • 4SC AG - Pipeline Products Glance
    • 4SC AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • 4SC AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • 4SC AG - Drug Profiles
    • resminostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vidofludimus
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 4SC-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 4SC-205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Malaria
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Neurological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Bromodomain for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • 4SC AG - Pipeline Analysis
    • 4SC AG - Pipeline Products by Target
    • 4SC AG - Pipeline Products by Route of Administration
    • 4SC AG - Pipeline Products by Molecule Type
    • 4SC AG - Pipeline Products by Mechanism of Action
  • 4SC AG - Recent Pipeline Updates
  • 4SC AG - Dormant Projects
  • 4SC AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • 4SC-203
      • 4SC-207
      • resminostat
  • 4SC AG - Company Statement
  • 4SC AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • 4SC AG, Key Information
  • 4SC AG, Key Facts
  • 4SC AG - Pipeline by Indication, 2016
  • 4SC AG - Pipeline by Stage of Development, 2016
  • 4SC AG - Monotherapy Products in Pipeline, 2016
  • 4SC AG - Partnered Products in Pipeline, 2016
  • 4SC AG - Partnered Products/ Combination Treatment Modalities, 2016
  • 4SC AG - Phase II, 2016
  • 4SC AG - Phase I, 2016
  • 4SC AG - Preclinical, 2016
  • 4SC AG - Discovery, 2016
  • 4SC AG - Pipeline by Target, 2016
  • 4SC AG - Pipeline by Route of Administration, 2016
  • 4SC AG - Pipeline by Molecule Type, 2016
  • 4SC AG - Pipeline Products by Mechanism of Action, 2016
  • 4SC AG - Recent Pipeline Updates, 2016
  • 4SC AG - Dormant Developmental Projects,2016
  • 4SC AG - Discontinued Pipeline Products, 2016

List of Figures

  • 4SC AG - Pipeline by Top 10 Indication, 2016
  • 4SC AG - Pipeline by Stage of Development, 2016
  • 4SC AG - Monotherapy Products in Pipeline, 2016
  • 4SC AG - Partnered Products in Pipeline, 2016
  • 4SC AG - Pipeline by Target, 2016
  • 4SC AG - Pipeline by Route of Administration, 2016
  • 4SC AG - Pipeline by Molecule Type, 2016
  • 4SC AG - Pipeline Products by Mechanism of Action, 2016
Back to Top